Abstract 657P
Background
T cell engagers (TCE) have been a breakthrough in pts care for multiple malignancies, and the number of phase I clinical trials testing TCE is exponential. The TCE score, based on lactate dehydrogenase (LDH) (LDH > 250 U/l : +1) and C reactive protein (CRP) (CRP > 10g/l : +1) levels, that was developed on a setting cohort (presented at ASCO annual meeting in 2023, Noé Herbel et al., JCO 41, 2573-2573(2023)), was shown to be prognostic for both overall survival (OS) and progression free survival (PFS), as pts with a high score (1-2) had a shorter OS and PFS, with a median PFS of less than two months : thus not presenting a sufficient clinical benefit from the treatment. To confirm the results obtained on the setting cohort, we aimed to prospectively confirm the prognostic ability of the TCE score on a validation cohort.
Methods
Every pts treated with a CD3 TCE in a phase I CT at the drug development department (DITEP) at Gustave Roussy which were not part of the setting cohort, with at least a two months follow up, were included in the validation cohort. Biological and clinical data were prospectively collected to calculate the TCE score, the OS and the PFS. Biological data were collected during the screening period. Estimation of OS and PFS was made using Kaplan-Meir method and comparison using log-rank test. Cox regression model was used in univariate analysis. Predictive power of the TCE score was analyzed using Harrell's C index.
Results
A total of 70 pts treated with CD3 TCE were included in the validation cohort. Median age was 60 years old. The most represented tumor type was ovarian adenocarcinoma (21%). Kaplan-Meier, log-rank test and cox regression model showed that pts with a low score had a longer PFS (HR : 0.42, 95%CI = 0.23 - 0.78, p = 0.005), with a median PFS of 1.8 months (m) for high-risk pts and 5.5 m for low-risk pts. It was also showed that low risk pts have a longer OS (HR : 0.41, 95%CI = 0.18 - 0.93, p = 0.03, with a median 8.7 m for high-risk pts and 12.4 m for low-risk pts. TCE score’s Harrell’s C index for PFS was 0.61 and 0.62 for OS.
Conclusions
The TCE score was developed on a setting cohort to be prognostic for OS and PFS in pts treated with bispecific TCE in phase I CT. We prospectively validated this score on an independent validation cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01